133 related articles for article (PubMed ID: 25595436)
1. Identification of potential pancreatic cancer serum markers: Increased sialyl-Lewis X on ceruloplasmin.
Balmaña M; Sarrats A; Llop E; Barrabés S; Saldova R; Ferri MJ; Figueras J; Fort E; de Llorens R; Rudd PM; Peracaula R
Clin Chim Acta; 2015 Mar; 442():56-62. PubMed ID: 25595436
[TBL] [Abstract][Full Text] [Related]
2. Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues.
Balmaña M; Duran A; Gomes C; Llop E; López-Martos R; Ortiz MR; Barrabés S; Reis CA; Peracaula R
Int J Biol Macromol; 2018 Jun; 112():33-45. PubMed ID: 29408556
[TBL] [Abstract][Full Text] [Related]
3. Biomarker identification in human pancreatic cancer sera.
Hanas JS; Hocker JR; Cheung JY; Larabee JL; Lerner MR; Lightfoot SA; Morgan DL; Denson KD; Prejeant KC; Gusev Y; Smith BJ; Hanas RJ; Postier RG; Brackett DJ
Pancreas; 2008 Jan; 36(1):61-9. PubMed ID: 18192883
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory cytokines regulate the expression of glycosyltransferases involved in the biosynthesis of tumor-associated sialylated glycans in pancreatic cancer cell lines.
Bassagañas S; Allende H; Cobler L; Ortiz MR; Llop E; de Bolós C; Peracaula R
Cytokine; 2015 Sep; 75(1):197-206. PubMed ID: 25934648
[TBL] [Abstract][Full Text] [Related]
5. Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein.
Chen J; Wu W; Chen L; Zhou H; Yang R; Hu L; Zhao Y
Pancreatology; 2013; 13(3):290-7. PubMed ID: 23719603
[TBL] [Abstract][Full Text] [Related]
6. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
Rychlíková J; Vecka M; Jáchymová M; Macášek J; Hrabák P; Zeman M; Vávrová L; Řoupal J; Krechler T; Ák A
Cancer Biomark; 2016 Jun; 17(1):55-65. PubMed ID: 27314293
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.
Zhang J; Zhao CY; Zhang SH; Yu DH; Chen Y; Liu QH; Shi M; Ni CR; Zhu MH
Oncol Rep; 2014 Mar; 31(3):1157-64. PubMed ID: 24398877
[TBL] [Abstract][Full Text] [Related]
9. Specific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis.
Ueda M; Kamada Y; Takamatsu S; Shimomura M; Maekawa T; Sobajima T; Fujii H; Nakayama K; Nishino K; Yamada M; Kobayashi Y; Kumada T; Ito T; Eguchi H; Nagano H; Miyoshi E
Pancreatology; 2016; 16(2):238-43. PubMed ID: 26897254
[TBL] [Abstract][Full Text] [Related]
10. Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis.
Maekawa T; Kamada Y; Ebisutani Y; Ueda M; Hata T; Kawamoto K; Takamatsu S; Mizutani K; Shimomura M; Sobajima T; Fujii H; Nakayama K; Nishino K; Yamada M; Kumada T; Ito T; Eguchi H; Nagano H; Miyoshi E
World J Gastroenterol; 2016 May; 22(17):4403-10. PubMed ID: 27158210
[TBL] [Abstract][Full Text] [Related]
11. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma.
Zhao C; Zhang J; Zhang S; Yu D; Chen Y; Liu Q; Shi M; Ni C; Zhu M
Oncol Rep; 2013 Jul; 30(1):276-84. PubMed ID: 23612862
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
[TBL] [Abstract][Full Text] [Related]
14. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation.
Campa D; Pastore M; Capurso G; Hackert T; Di Leo M; Izbicki JR; Khaw KT; Gioffreda D; Kupcinskas J; Pasquali C; Macinga P; Kaaks R; Stigliano S; Peeters PH; Key TJ; Talar-Wojnarowska R; Vodicka P; Valente R; Vashist YK; Salvia R; Papaconstantinou I; Shimizu Y; Valsuani C; Zambon CF; Gazouli M; Valantiene I; Niesen W; Mohelnikova-Duchonova B; Hara K; Soucek P; Malecka-Panas E; Bueno-de-Mesquita HBA; Johnson T; Brenner H; Tavano F; Fogar P; Ito H; Sperti C; Butterbach K; Latiano A; Andriulli A; Cavestro GM; Busch ORC; Dijk F; Greenhalf W; Matsuo K; Lombardo C; Strobel O; König AK; Cuk K; Strothmann H; Katzke V; Cantore M; Mambrini A; Oliverius M; Pezzilli R; Landi S; Canzian F
Int J Cancer; 2018 Jan; 142(2):290-296. PubMed ID: 28913878
[TBL] [Abstract][Full Text] [Related]
15. Microfibril associated protein 4 (MFAP4) is a carrier of the tumor associated carbohydrate sialyl-Lewis x (sLe
Guerrero PE; Duran A; Ortiz MR; Castro E; Garcia-Velasco A; Llop E; Peracaula R
J Proteomics; 2021 Jan; 231():104004. PubMed ID: 33038510
[TBL] [Abstract][Full Text] [Related]
16. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
17. Autoantibody signature in human ductal pancreatic adenocarcinoma.
Tomaino B; Cappello P; Capello M; Fredolini C; Ponzetto A; Novarino A; Ciuffreda L; Bertetto O; De Angelis C; Gaia E; Salacone P; Milella M; Nisticò P; Alessio M; Chiarle R; Giuffrida MG; Giovarelli M; Novelli F
J Proteome Res; 2007 Oct; 6(10):4025-31. PubMed ID: 17824682
[TBL] [Abstract][Full Text] [Related]
18. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
[TBL] [Abstract][Full Text] [Related]
19. Subclinical Inflammation and Endothelial Dysfunction in Patients with Chronic Pancreatitis and Newly Diagnosed Pancreatic Cancer.
Gasiorowska A; Talar-Wojnarowska R; Kaczka A; Borkowska A; Czupryniak L; Małecka-Panas E
Dig Dis Sci; 2016 Apr; 61(4):1121-9. PubMed ID: 26597191
[TBL] [Abstract][Full Text] [Related]
20. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers.
Nakano M; Nakagawa T; Ito T; Kitada T; Hijioka T; Kasahara A; Tajiri M; Wada Y; Taniguchi N; Miyoshi E
Int J Cancer; 2008 May; 122(10):2301-9. PubMed ID: 18214858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
